Pharmacogenetic Approach to Tramadol Use in the Arab Population.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Analgesics, Opioid*/therapeutic use ; Arabs*/genetics ; Cytochrome P-450 CYP2D6*/genetics ; Pain, Postoperative*/drug therapy ; Pain, Postoperative*/genetics ; Receptors, Opioid, mu*/genetics ; Tramadol*/therapeutic use; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Pharmacogenetics/methods ; Polymorphism, Single Nucleotide

Tramdol is one of most popular opioids used for postoperative analgesia worldwide. Among Arabic countries, there are reports that its dosage is not appropriate due to cultural background. To provide theoretical background of the proper usage of tramadol, this study analyzed the association between several genetic polymorphisms (CYP2D6/OPRM1) and the effect of tramadol. A total of 39 patients who took tramadol for postoperative analgesia were recruited, samples were obtained, and their DNA was extracted for polymerase chain reaction products analysis followed by allelic variations of CYP2D6 and OPRM A118G determination. Numerical pain scales were measured before and 1 h after taking tramadol. The effect of tramadol was defined by the difference between these scales. We concluded that CYP2D6 and OPRM1 A118G single nucleotide polymorphisms may serve as crucial determinants in predicting tramadol efficacy and susceptibility to post-surgical pain. Further validation of personalized prescription practices based on these genetic polymorphisms could provide valuable insights for the development of clinical guidelines tailored to post-surgical tramadol use in the Arabic population.

J Neurochem. 2007 Oct;103(1):77-87. (PMID: 17877633)
Nat Med. 2024 Jul;30(7):1874-1881. (PMID: 39030405)
J Pain Palliat Care Pharmacother. 2011;25(1):6-18. (PMID: 21426212)
Clin Pharmacol Ther. 2007 Jul;82(1):41-7. (PMID: 17361124)
Clin Pharmacol Ther. 1992 Jan;51(1):12-7. (PMID: 1346258)
Cancer. 2012 Mar 15;118(6):1718-25. (PMID: 21837673)
J Clin Psychopharmacol. 2008 Feb;28(1):78-83. (PMID: 18204346)
Mil Med. 2016 May;181(5):397-9. (PMID: 27136641)
J Headache Pain. 2012 Oct;13(7):513-9. (PMID: 22752568)
Pain. 2007 Nov;132(1-2):18-22. (PMID: 17706868)
Annu Rev Med. 2006;57:119-37. (PMID: 16409140)
J Med Genet. 2012 Jan;49(1):1-9. (PMID: 22058430)
Fundam Clin Pharmacol. 2010 Aug;24(4):517-24. (PMID: 19845769)
J Pain. 2005 Mar;6(3):159-67. (PMID: 15772909)
Pharmacogenet Genomics. 2009 Jun;19(6):429-36. (PMID: 19514130)
J Biol Chem. 2009 Mar 6;284(10):6530-5. (PMID: 19116204)
Clin Biochem. 2014 Sep;47(13-14):1169-87. (PMID: 24912048)
J Neurosci. 2012 Jul 18;32(29):9831-4. (PMID: 22815498)
Pharmacol Res. 2007 Feb;55(2):122-30. (PMID: 17175164)
Clin J Pain. 2017 Dec;33(12):1117-1130. (PMID: 28379874)
Palliat Support Care. 2013 Feb;11(1):1-4. (PMID: 22874103)
Pain. 2008 Sep 30;139(1):5-14. (PMID: 18403122)
Eur J Clin Pharmacol. 2006 Jul;62(7):513-21. (PMID: 16763825)
Clin Pharmacokinet. 2009;48(12):761-804. (PMID: 19902987)
Pain Physician. 2015 Mar-Apr;18(2):131-52. (PMID: 25794200)
J Biol Chem. 2005 Sep 23;280(38):32618-24. (PMID: 16046395)
Minerva Anestesiol. 2011 Jan;77(1):33-9. (PMID: 21150856)
Eur J Pain. 2009 Nov;13(10):1036-42. (PMID: 19167252)
J Clin Pharmacol. 2012 Feb;52(2):234-42. (PMID: 21383334)
Clin Pharmacol Ther. 2015 Aug;98(2):127-34. (PMID: 25974703)
Ann Gen Psychiatry. 2018 Jun 01;17:22. (PMID: 29881439)
Clin Transl Sci. 2020 Jan;13(1):116-124. (PMID: 31647186)
Pharmacol Ther. 2007 Dec;116(3):496-526. (PMID: 18001838)
Clin Chim Acta. 2010 Dec 14;411(23-24):2043-8. (PMID: 20828547)
Pharmgenomics Pers Med. 2016 Dec 01;9:131-147. (PMID: 27942231)
Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):993-1004. (PMID: 22230405)
Trends Genet. 2012 Jun;28(6):258-66. (PMID: 22464640)
Mol Pain. 2009 Sep 23;5:56. (PMID: 19775452)
PLoS One. 2011;6(12):e28943. (PMID: 22216145)
Pharmacol Biochem Behav. 2014 Aug;123:25-33. (PMID: 24201053)
Clin Lab Med. 2016 Sep;36(3):493-506. (PMID: 27514464)
J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-61. (PMID: 20183526)
Pain. 2007 Sep;131(1-2):3.e1-4. (PMID: 17574758)
Hum Mol Genet. 2012 Nov 1;21(21):4751-60. (PMID: 22875838)
Eur J Clin Pharmacol. 2005 Jun;61(4):257-66. (PMID: 15906019)
Annu Rev Pharmacol Toxicol. 2009;49:97-121. (PMID: 18834308)
Clin Pharmacol Ther. 1993 Apr;53(4):410-8. (PMID: 8097442)
Clin Pharmacol Ther. 2020 Jan;107(1):154-170. (PMID: 31544239)
Health Psychol. 2010 Mar;29(2):134-42. (PMID: 20230086)
Drugs. 2000 Jul;60(1):139-76. (PMID: 10929933)
Clin Pharmacol Ther. 2002 Jul;72(1):76-89. (PMID: 12152006)
Int J Clin Pharmacol Ther. 2013 May;51(5):383-92. (PMID: 23557865)

Keywords: Arab; CYP2D6; OPRM1 A118G; pharmacogenetics; tramadol

0 (Analgesics, Opioid)
EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
0 (OPRM1 protein, human)
0 (Receptors, Opioid, mu)
39J1LGJ30J (Tramadol)

Date Created: 20240829 Date Completed: 20240829 Latest Revision: 20240903

20250114

PMC11354576

10.3390/ijms25168939

39201627